Kala Pharmaceuticals to Present at Upcoming Investor Conferences
Date:
Presentation Time:
Location:
2018
Date:
Presentation Time:
Location:
Date:
Fireside Chat Time:
Location:
To access a live webcast and subsequent archived recording of the presentation, please visit “Events” in the “Investors” section of the Kala website at http://kalarx.com/.
About Kala
Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary Mucus Penetrating Particle (MPP) technology, with an initial focus on the treatment of eye diseases. Kala has applied the MPP technology to a corticosteroid, LE, designed for ocular applications, resulting in the recent approval of INVELTYS for the treatment of inflammation and pain following ocular surgery. Kala plans to submit a New Drug Application for KPI-121 0.25%, for the temporary relief of the signs and symptoms of dry eye disease in the second half of 2018.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180829005705/en/
Source:
For Kala Pharmaceuticals, Inc.
Investors
Michael Schaffzin, 212-362-1200
michael@sternir.com
or
Media
Kari Watson, 781-235-3060
kwatson@macbiocom.com